Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation. The collaboration aims to develop and make available a real-world multimodal, deidentified FL data library in Lens – Tempus’ data analytics platform – through which researchers may derive AI-driven insights to accelerate the development of FL treatments in an effort to improve patient outcomes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- CVS Health, Lyft report Q4 results: Morning Buzz
- Tesla, Instacart initiated: Wall Street’s top analyst calls
- William Blair downgrades Tempus AI on valuation after rally
- Tempus AI downgraded to Market Perform from Outperform at William Blair
- Tempus AI COO Ryan Fukushima sells 20,000 shares of stock
Questions or Comments about the article? Write to editor@tipranks.com